Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.
复制标题
DOI：
10.1002/hep.27016
复制
发表时间：
2014-09
期刊：
影响因子：
13.5
通讯作者：
Pischon, Tobias
中科院分区：
文献类型：
--
作者：
Aleksandrova, Krasimira;Boeing, Heiner;Noethlings, Ute;Jenab, Mazda;Fedirko, Veronika;Kaaks, Rudolf;Lukanova, Annekatrin;Trichopoulou, Antonia;Trichopoulos, Dimitrios;Boffetta, Paolo;Trepo, Elisabeth;Westhpal, Sabine;Duarte-Salles, Talita;Stepien, Magdalena;Overvad, Kim;Tjonneland, Anne;Halkjaer, Jytte;Boutron-Ruault, Marie-Christine;Dossus, Laure;Racine, Antoine;Lagiou, Pagona;Bamia, Christina;Benetou, Vassiliki;Agnoli, Claudia;Palli, Domenico;Panico, Salvatore;Tumino, Rosario;Vineis, Paolo;Bueno-De-Mesquita, Bas;Peeters, Petra H.;Gram, Inger Torhild;Lund, Eiliv;Weiderpass, Elisabete;Quiros, J. Ramon;Agudo, Antonio;Sanchez, Maria-Jose;Gavrila, Diana;Barricarte, Aurelio;Dorronsoro, Miren;Ohlsson, Bodil;Lindkvist, Bjoern;Johansson, Anders;Sund, Malin;Khaw, Kay-Tee;Wareham, Nicholas;Travis, Ruth C.;Riboli, Elio;Pischon, Tobias
肥胖和相关的代谢紊乱与肝癌发生有关;然而，关于肥胖相关的生物标志物对肝癌风险的作用的数据很少。我们在欧洲癌症与营养前瞻性研究的一项巢式病例对照研究中，前瞻性研究了炎症和代谢生物标志物与肝细胞癌（HCC）、肝内胆管癌（IBD）、肝外胆囊癌和胆道癌（GBTC）风险的相关性。在平均7.7年的时间里，296名参与者发展为HCC（n = 125），GBTC（n = 137）或IBD（n = 34）。使用风险集抽样，以2：1的比例选择对照组，并根据招募中心、年龄、性别、空腹状态和采血时间进行匹配。测量基线血清C反应蛋白（CRP）、白细胞介素-6（IL-6）、C肽、总高分子量（HMW）脂联素、瘦素、胎球蛋白-a和谷氨酸脱氢酶（GLDH）浓度，采用条件Logistic回归估计发病率比（IRR）和95%可信区间（CI）。在调整生活方式因素、糖尿病、肝炎感染和肥胖指标后，CRP、IL-6、C肽和非HMW脂联素浓度升高与HCC风险升高相关（每倍浓度的IRR = 1.22; 95% CI = 1.02-1.46; P = 0.03; 1.90; 95% CI = 1.30-2.77; P = 0.001; 2.25; 95% CI = 1.43-3.54; P = 0.0005;和2.09; 95%CI = 1.19-3.67; P = 0.01）。CRP也与GBTC风险相关（IRR = 1.22; 95%CI = 1.05-1.42; P = 0.01）。GLDH与HCC（IRR = 1.62; 95% CI = 1.25-2.11; P = 0.0003）和IBD（IRR = 10.5; 95% CI = 2.20-50.90; P = 0.003）的风险相关。CRP、IL-6、C肽和非高分子量脂联素的连续净重新分类指数为0.63，GLDH的连续净重新分类指数为0.46，表明这些生物标志物具有良好的预测能力。结论：炎症和高胰岛素血症的生物标志物水平升高与HCC的高风险相关，独立于肥胖和已确定的肝癌风险因素。（肝病学2014;60：858-871）
Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n = 125), GBTC (n = 137), or IBD (n = 34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations = 1.22; 95% CI = 1.02-1.46; P = 0.03; 1.90; 95% CI = 1.30-2.77; P = 0.001; 2.25; 95% CI = 1.43-3.54; P = 0.0005; and 2.09; 95% CI = 1.19-3.67; P = 0.01, respectively). CRP was associated also with risk of GBTC (IRR = 1.22; 95% CI = 1.05-1.42; P = 0.01). GLDH was associated with risks of HCC (IRR = 1.62; 95% CI = 1.25-2.11; P = 0.0003) and IBD (IRR = 10.5; 95% CI = 2.20-50.90; P = 0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. Conclusion: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. (Hepatology 2014;60:858–871)
登录
查看更多内容
影响因子：
2
作者：
DURRLEMAN, S;SIMON, R
通讯作者：
SIMON, R
DOI：
10.1007/978-3-642-03503-6_8
发表时间：
2011-01-01
期刊：
INFLAMMATION AND GASTROINTESTINAL CANCERS
影响因子：
--
作者：
Alison, Malcolm R.;Nicholson, Linda J.;Lin, Wey-Ran
通讯作者：
Lin, Wey-Ran
影响因子：
7
作者：
Doyle, Suzanne L.;Donohoe, Claire L.;Reynolds, John V.
通讯作者：
Reynolds, John V.
影响因子：
3.8
作者：
Khattab, Mahmoud A.;Eslam, Mohammed;Sharawe, Mohammed A.
通讯作者：
Sharawe, Mohammed A.
影响因子：
10.3
作者：
Bao, Ying;Giovannucci, Edward L.;Wolpin, Brian M.
通讯作者：
Wolpin, Brian M.